Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02296645 · ClinicalTrials.gov registry record · Phase 2
Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™ (ZX-ZP-0055)
A Phase 2 study of Surgical Site Infection, sponsored by Zurex Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 1
- Study location
NCT02296645: Completed Phase 2 study of Surgical Site Infection, sponsored by Zurex Pharma.
NCT02296645 is a Phase 2 study of Surgical Site Infection that has completed, run by Zurex Pharma. The registered enrollment target is 36 participants, below the 567-participant average among 25 other Surgical Site Infection trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02296645, a Phase 2 study of Surgical Site Infection, has completed, sponsored by Zurex Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a randomized, paired-comparisons design where each subject receives two of the planned treatments.
Primary Outcome
The primary measure of antimicrobial efficacy is the log10 reduction of skin flora on the abdominal and groin sites 10 minutes following application of the study treatments relative to the Treatment Day baseline log10 counts.
Conditions Studied
Interventions
- DRUG ZuraPrep
- DRUG ChloraPrep
Study Locations (1)
Virginia
- MicroBioTest Laboratories - Sterling
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2014-11 |
| Est. Completion | 2015-01 |
| Phase | Phase 2 |
What the finished NCT02296645 record still lists
NCT02296645 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 567-participant average among 25 other Surgical Site Infection trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Surgical Site Infection appearing as the primary indexed condition, and to 2 interventions - of which ZuraPrep is the first listed.
NCT02296645 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT02296645 about?
NCT02296645 is a clinical study titled "Efficacy Study to Evaluate Antimicrobial Effectiveness of ZuraPrep™ (ZX-ZP-0055)". This is a randomized, paired-comparisons design where each subject receives two of the planned treatments.
What is the current status of trial NCT02296645?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2014-11. Estimated completion is 2015-01.
What conditions does trial NCT02296645 study?
This clinical trial studies the following conditions: Surgical Site Infection.
What interventions are being tested in trial NCT02296645?
The interventions under investigation include: ZuraPrep (DRUG), ChloraPrep (DRUG).
Who is sponsoring clinical trial NCT02296645?
This trial is sponsored by Zurex Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02296645 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Surgical Site Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02296645's enrollment target sits among peer trials
36 23rd of 25 higher than 3 of 25 other Surgical Site Infection trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Surgical Site Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Topical Treatment and Prevalence of P. Acnes
COMPLETED · Phase 2
-
Effect of Exeporfinium Chloride (XF-73) Gel on Nasal S.Aureus in Patients at Risk of Post-op Staphylococcal Infection
COMPLETED · Phase 2
-
Zinc Oxide Versus Petrolatum Following Skin Surgery
RECRUITING · Early Phase 1
-
Diluted Aqueous Povidone-Iodine Compared to Saline to Decrease Surgical Site Infections
RECRUITING · Phase 3
-
Decolonization to Reduce After-Surgery Events of Surgical Site Infection
RECRUITING · Phase 4
-
Studying How Outpatient Water affEcts Risks With Drains (SHOWER Study)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia